Market Place
Sourcing Support
AbbVie looks to extend Rinvoq`s reach with filings for giant cell arteritis
13 Jul 2024 //
PRESS RELEASE
RINVOQ Available For Pediatric Polyarticular JIA And Psoriatic Arthritis
04 Jun 2024 //
PR NEWSWIRE
J&J acquires experimental skin disorder drug for $1.25 billion
29 May 2024 //
BIOPHARMADIVE
RINVOQ® Beats DUPIXENT® in Head-to-Head Atopic Dermatitis Study
25 Apr 2024 //
PR NEWSWIRE
AbbVie`s phase 3 Select -GCA study of Upadacitinib showed positive results
23 Apr 2024 //
INDINPHARMAPOST
Upadacitinib`s Phase 3 GCA Study Met Primary Endpoint
18 Apr 2024 //
PR NEWSWIRE
AbbVie`s Rinvoq passes muster in yet another autoimmune disease
18 Apr 2024 //
FIERCE PHARMA
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
03 Feb 2024 //
REUTERS
AbbVie files patent litigation against generic Rinvoq makers
23 Nov 2023 //
FIERCE PHARMA
AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis
13 Oct 2023 //
CLINICAL TRIALS ARENA
AbbVie Presents Data Supporting the Efficacy and Safety Profile of RINVOQ
11 Oct 2023 //
PR NEWSWIRE
Health Canada Approves AbbVie`s Rinvoq for Moderately to Severely Active UC
26 Jul 2023 //
NEWSWIRE
AbbVie Advances Pipeline with First Patient Dosed in PIII Trial of Upadacitinib
24 Jul 2023 //
PRESS RELEASE
AbbVie`s Rinvoq passes midstage test in SLE
01 Jun 2023 //
FIERCE PHARMA
New England Journal of Medicine Publishes Results from Phase 3 of Upadacitinib
25 May 2023 //
PR NEWSWIRE
AbbVie Presents Data Further Supporting the Efficacy Profile of RINVOQ
24 May 2023 //
PRESS RELEASE
With FDA nod for Crohn`s, AbbVie wins 7th indication for Rinvoq
19 May 2023 //
FIERCE PHARMA
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology at 2023
06 May 2023 //
PR NEWSWIRE
Abbvie Revenues Down 10% in the Quarter
01 May 2023 //
CONTRACT PHARMA
AbbVie Announces European Commission Approval of Rinvoq
18 Apr 2023 //
PR NEWSWIRE
AbbVie Advances RINVOQ to Phase 3 Trials in Systemic Lupus Erythematosus
24 Mar 2023 //
PRESS RELEASE
AbbVie Gets Positive CHMP Opinion For Upadacitinib For Crohn`s Diseas
28 Feb 2023 //
NASDAQ
AbbVie top TV drug ad spender in January
06 Feb 2023 //
FIERCE PHARMA
MHRA approves first oral advanced therapy for Crohn’s disease
02 Feb 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Abbvie raises sales outlook of two immunology drugs to $17.5 bln in 2025
10 Jan 2023 //
REUTERS
Singapore’s HSA finds benefits outweigh risks for JAK inhibitors
20 Dec 2022 //
RAPS
Scottish Medicines Consortium agrees to use of Rinvoq
13 Dec 2022 //
PHARMATIMES
BMS` Zeposia, AbbVie drugs shake up early IBD market
06 Dec 2022 //
FIERCEPHARMA
AbbVie`s Rinvoq topples Dupixent as the top TV drug ad spender
06 Dec 2022 //
FIERCEPHARMA
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
01 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
AbbVie preps for an onslaught of Humira biosimilars in 2023 & Skyrizi and Rinvoq
29 Oct 2022 //
ENDPTS
RINVOQ (Upadacitinib) Receives Its Sixth U.S. FDA Approval
22 Oct 2022 //
PRESS RELEASE
AbbVie continues top TV drug ad spender reign
10 Oct 2022 //
FIERCEPHARMA
RINVOQ Approved by EC as an Oral Treatment in Active NRA Spondyloarthritis
29 Jul 2022 //
PRNEWSWIRE
AbbVie Submits Regulatory Application to FDA & EMA for Rinvoq in Crohn`s Disease
27 Jul 2022 //
PRNEWSWIRE
NICE recommend’s use of Leo Pharma’s Adtralza
07 Jul 2022 //
PHARMATIMES
NICE recommends dermatitis treatment for use in NHS England and Wales
30 Jun 2022 //
PHARMAFILE
NICE recommends AbbVie’s Rinvoq for atopic dermatitis
30 Jun 2022 //
THEPHARMALETTER
CHMP Recommends Approval of Upadacitinib for nr-axSpA
27 Jun 2022 //
PRNEWSWIRE
AbbVie revs up Rinvoq with first eczema ad
06 Jun 2022 //
FIERCEPHARMA
The Lancet Publishes Results from PIII Programs of Upadacitinib
26 May 2022 //
PRNEWSWIRE
CHMP Recommends European Commission Approval of Upadacitinib in UC
24 May 2022 //
PRESS RELEASE
Rinvoq passes PhIII maintenance study for Crohn`s disease
13 May 2022 //
ENDPTS
RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults
16 Mar 2022 //
PRESS RELEASE
2nd Phase 3 Induction Study Confirms Upadacitinib Improved Outcomes
24 Feb 2022 //
PRNEWSWIRE
AbbVie submits applications for treatment of chronic disease
14 Feb 2022 //
PHARMAFILE
EMA initiates safety review on JAK inhibitors; Galapagos woes continue
12 Feb 2022 //
ENDPTS
AbbVie Showcases Its Leadership in Research in IBD at the 17th ECCO
01 Feb 2022 //
PRNEWSWIRE
AbbVie`s Rinvoq hunts for ankylosing spondylitis nods in EU, US
11 Jan 2022 //
FIERCEPHARMA
AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025
11 Jan 2022 //
PRESS RELEASE
The NICE recommends Rinvoq for psoriatic arthritis patients
10 Jan 2022 //
PHARMATIMES
AbbVie Submits Applications for Upadacitinib to U.S. FDA & EMA
07 Jan 2022 //
PRNEWSWIRE
AbbVie`s Rinvoq, Pfizer`s Xeljanz nab JAK label expansions
16 Dec 2021 //
FIERCEPHARMA
RINVOQ Receives FDA Approval for Active Psoriatic Arthritis
14 Dec 2021 //
PRNEWSWIRE
